An interventional study of Dexmedetomidine and lidocaine in Anesthesia, Anesthesia Complication and Surgery, sponsored by CHU de Quebec-Universite Laval. Active, not recruiting at 5 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by CHU de Quebec-Universite Laval · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies testing dexmedetomidine in Pain, Postoperative — 35 open to participants now, 38 under way, 5 of them phase 3. Dexmedetomidine · Pain, Postoperative.
Among the 136 studies testing dexmedetomidine in Pain, Postoperative, this one is the 37th largest by planned enrollment, is one of 16 that started in 2025, is one of 47 with no phase, reaches primary completion later than 21 of the 37 other live ones, and was the 104th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →35 of the 136 studies testing dexmedetomidine in Pain, Postoperative are open now, in 9 countries. Recruiting first, the newest first:
Minia University · Sites in Egypt
Ages 18–70
Vasiliki Samartzi · Sites in Greece
Ages 20–70 · Women only
Tanta University · Sites in Egypt
Ages 21–60
Beijing Tiantan Hospital · Sites in China
Ages 18–65
Rhode Island Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 23 · Phase 4 49
First in 2008; this study’s year is marked. 16 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 85 across the 136 interventional studies. Of the 70 that completed or were terminated, 8 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 136 have an industry lead sponsor. The 10 most frequent:
CHU de Quebec-Universite Laval is the lead sponsor of 137 studies on the registry; 27 are open to participants now.
CHU de Quebec-Universite Laval has 4 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
15 of the studies testing dexmedetomidine in Pain, Postoperative that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07878156Phase 3Children's Cancer Hospital Egypt 57357Dexmedetomidine Use for Greater Occipital Nerve Block in Pediatric Posterior Fossa Tumor Surgery. | 2026-12-30 |
| NCT07434310Phase 3Dr. Naveed SiddiquiUse of Dexmedetomidine to Improve Pain Control and Recovery After Laparocopic-Assisted Bowel Surgery in Adults | 2027-07-01 |
| NCT07847047Phase 3Assiut UniversitySafety and Efficacy of Dexamethasone Versus Dexmedetomidine as Adjuvants in PENG Block in Hip Surgeries for Postoperative Pain Management | 2027-10 |
| NCT07846722Vasiliki SamartziEsmolol Versus Dexmedetomidine for Opioid-sparing in Laparoscopic Gynecological Surgery | 2026-12-01 |
| NCT07099222University of ArizonaEfficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 136 studies testing dexmedetomidine in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Up to 40% of patients experience suboptimal recovery in the days following major surgery, limiting their return to functional independence. Few preventive interventions exist, but intravenous dexmedetomidine and lidocaine administered during general anesthesia represent simple strategies that may significantly impact recovery and other patient-centred outcomes after surgery. The goal of this pilot trial is to determine the feasibility of conducting a phase 3 pragmatic adaptive multicentre trial to evaluate the impact of dexmedetomidine and lidocaine administered during major non-cardiac surgery on patient-centred outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dexmedetomidine
Drug: lidocaine
Other: control group
Intravenous bolus: between 0.2 and 0.5 mcg/kg. followed by Intravenous infusion: ranging from 0.2 to 0.7 mcg/kg/h to the discretion of the attending anesthesiologist. Bolus will be initiated prior to surgical incision and infusion will be stopped at wound closure.
Intravenous bolus: between 0.5 and 1.5 mg/kg. followed by Intravenous infusion: ranging from 0.5 to 2.0 mg/kg/h to the discretion of the attending anesthesiologist. Bolus will be initiated prior to surgical incision and infusion will be stopped at wound closure.
Usual care where systemic dexmedetomidine is not allowed and systemic lidocaine is permitted only for the prevention or treatment of propofol injection pain.
Recruitment rate
Number of patients who are approached to participate by the study team and who consent to participate in the study.
Time frame: 1 week
Proportion of participants receiving dexmedetomidine
Proportion of patients in the dexmedetomidine group who receive per protocol treatment (i.e. they receive dexmedetomidine during general anesthesia).
Time frame: 24 hours
Proportion of participants receiving lidocaine
Proportion of patients in the lidocaine group who receive per protocol treatment (i.e. they receive lidocaine during general anesthesia).
Time frame: 24 hours
Completeness of data collection for outcome measures
Completeness of data collection, defined as the percentage of instruments or data fields completed with at least 90% of expected forms or relevant fields completed at each time point for each instrument and participant.
Time frame: 6 months
Sex representativeness of participants
Proportion of female participants enrolled in the trial.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Apr 2027, 21 months after the start.
Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 21 months is above that.
Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexmedetomidine · Lidocaine
CHU de Quebec-Universite Laval →